• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Long-term safety of repeated high doses of incobotulinumtoxinA injections for the treatment of upper and lower limb spasticity after stroke
Current guidelines suggested a dosage up to 600units (U) of botulinum toxin type A (BoNT-A) (onabotulinumtoxinA or incobotulinumtoxinA) in reducing spastic hypertonia with low prevalence of complications, although a growing body of evidence showed efficacy with the use of high doses (>800U). The available evidence mainly referred to a single set of injections evaluating the efficacy and safety of the neurotoxin 30days after the treatment. In a prospective, non-randomized, open-label study, we studied the safety of repeated higher doses of incobotulinumtoxinA in post-stroke upper and lower limb spasticity.
Source: Journal of the Neurological Sciences - May 1, 2017 Category: Neurology Authors: Andrea Santamato, Francesco Panza, Domenico Intiso, Alessio Baricich, Alessandro Picelli, Nicola Smania, Francesca Fortunato, Davide Seripa, Pietro Fiore, Maurizio Ranieri Source Type: research

Sensorimotor Modulation by Botulinum Toxin A in Post-Stroke Arm Spasticity: Passive Hand Movement
In post-stroke spasticity, functional imaging may uncover modulation in the central sensorimotor networks associated with botulinum toxin type A (BoNT) therapy. Investigations were performed to localize brain activation changes in stroke patients treated with BoNT for upper limb spasticity using functional magnetic resonance imaging (fMRI).
Source: Journal of the Neurological Sciences - January 11, 2016 Category: Neurology Authors: Tomáš Veverka, Petr Hluštík, Pavel Hok, Pavel Otruba, Jana Zapletalová, Zbyněk Tüdös, Alois Krobot, Petr Kaňovský Source Type: research

Efficacy and Safety of NABOTA in Post-stroke Upper Limb Spasticity: A phase 3 multicenter, double-blinded, randomized controlled trial
Botulinum toxin A is widely used in the clinics to reduce spasticity and improve upper limb function for post-stroke patients. Efficacy and safety of a new botulinum toxin type A, NABOTA (DWP450) in post-stroke upper limb spasticity was evaluated in comparison with Botox (Onabotulinum toxin A). A total of 197 patients with post-stroke upper limb spasticity were included in this study and randomly assigned to NABOTA group (n=99) or Botox group (n=98). Wrist flexors with modified Ashworth Scale (MAS) grade 2 or greater, and elbow flexors, thumb flexors and finger flexors with MAS 1 or greater were injected with either drug.
Source: Journal of the Neurological Sciences - July 21, 2015 Category: Neurology Authors: Hyung Seok Nam, Yoon Ghil Park, Nam-Jong Paik, Byung-Mo Oh, Min Ho Chun, Hea-Eun Yang, Dae Hyun Kim, Youbin Yi, Han Gil Seo, Kwang Dong Kim, Min Cheol Chang, Jae Hak Ryu, Shi-Uk Lee Source Type: research

Employment of Higher Doses of Botulinum Toxin Type A to Reduce Spasticity After Stroke
Spasticity is a common disabling symptom for several neurological conditions. Botulinum toxin type A injection represents the gold standard treatment for focal spasticity with efficacy, reversibility, and low prevalence of complications. Current guidelines suggest a dose up to 600 units (U) of onabotulinumtoxinA/incobotulinumtoxinA or up to 1500 U of abobotulinumtoxinA to treat post-stroke spasticity to avoid important adverse effects. However, recently, higher doses of botulinum toxin type A were employed, especially in case of upper and lower limb severe spasticity.
Source: Journal of the Neurological Sciences - February 5, 2015 Category: Neurology Authors: Andrea Santamato, Maria Francesca Micello, Maurizio Ranieri, Giovanni Valeno, Antonio Albano, Alessio Baricich, Carlo Cisari, Domenico Intiso, Alberto Pilotto, Giancarlo Logroscino, Francesco Panza Source Type: research

Can botulinum toxin type A injection technique influence the clinical outcome of patients with post-stroke upper limb spasticity? A randomized controlled trial comparing manual needle placement and ultrasound-guided injection techniques
Botulinum toxin type A is a first-line treatment for post-stroke focal spasticity, and the accuracy in delivering the toxin to the target muscles may influence the treatment outcome. Our aim was to compare the reduction of spasticity and the related finger position at rest improvement in post-stroke patients treated with botulinum toxin type A in upper limb muscles using ultrasound guidance and manual needle placement.
Source: Journal of the Neurological Sciences - September 18, 2014 Category: Neurology Authors: Andrea Santamato, Maria Francesca Micello, Francesco Panza, Francesca Fortunato, Alessio Baricich, Carlo Cisari, Alberto Pilotto, Giancarlo Logroscino, Pietro Fiore, Maurizio Ranieri Source Type: research

Cortical activity modulation by botulinum toxin type A in patients with post-stroke arm spasticity: Real and imagined hand movement
Our aim was to use functional magnetic resonance imaging (fMRI) to compare brain activation changes due to botulinum toxin A (BoNT) application between two chronic stroke patient groups with different degree of weakness treated for upper limb spasticity.
Source: Journal of the Neurological Sciences - September 14, 2014 Category: Neurology Authors: Tomáš Veverka, Petr Hluštík, Pavel Hok, Pavel Otruba, Zbyněk Tüdös, Jana Zapletalová, Alois Krobot, Petr Kaňovský Source Type: research

Efficacy and safety of botulinum toxin type A (Dysport) for the treatment of post-stroke arm spasticity: Results of the German–Austrian open-label post-marketing surveillance prospective study
Abstract: The current practice in Germany and Austria, and the safety and efficacy of botulinum toxin type A (BoNT-A; Dysport) in the treatment of patients with post-stroke arm spasticity (with no fixed upper-limb contractures), were assessed in this observational prospective non-interventional study. One treatment cycle was documented with assessments at baseline, approximately week 4 (optional), and approximately week 12. Pattern of spasticity, treatment goal, safety and efficacy were recorded. Overall response and goal achievement was rated on a 4-point scale (‘no goal achievement’, ‘goal achievement’, ‘good g...
Source: Journal of the Neurological Sciences - December 23, 2013 Category: Neurology Authors: Wolfgang H. Jost, Harald Hefter, Andrea Reissig, Katja Kollewe, Joerg Wissel Tags: Original Articles Source Type: research